Tumour suppression by the human von hippel-lindau gene product

Nature Medicine

Volumn 1, Issue 8, 1995, Pages 822-826

  Iliopoulos, Othon ^a   Kibel, Adam ^a   Gray, Steven ^a   Kaelin, William G ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT;

ARTICLE; CANCER INHIBITION; CASE REPORT; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; VON HIPPEL LINDAU DISEASE;

AMINO ACID SEQUENCE; BASE SEQUENCE; BLOTTING, NORTHERN; CARCINOMA; CELL COMPARTMENTATION; CELL TRANSFORMATION, NEOPLASTIC; CYTOPLASM; FLUORESCENT ANTIBODY TECHNIQUE; GENES, TUMOR SUPPRESSOR; HIPPEL-LINDAU DISEASE; HUMAN; KIDNEY NEOPLASMS; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDE MAPPING; PROTEINS; RECOMBINANT FUSION PROTEINS; SUPPORT, NON-U.S. GOV'T; TRANSCRIPTION, GENETIC; TRANSLATION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0029090338     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm0895-822     Document Type: Article

References (30)

1. Malkin, D. et al., Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233-1238 (1990).
2. McKusick, V.A. Mendelian Inheritance in Man (The Johns Hopkins University Press, Baltimore and London, 1992).
3. Latif, F. et al., Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260, 1317-1320 (1993).
4. Chen, F. et al., Germ line mutations in the von Hippel-Lindau disease tumor suppressor gene: Correlations with phenotype. Hum. Mutat. 5, 66-75 (1995).
5. Shuin, T. et al., Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res. 54, 2852-2855 (1994).
6. Gnarra, J.R. et al., Mutations of the VHL tumour suppressor gene in renal carcinoma. Nature Genet. 7, 85-90 (1994).
7. Kanno, H. et al., Somatic mutations of the von Hippel-Lindau Tumor supressor gene in sporadic central nervous systems hemangioblastomas. Cancer Res. 54, 4845-4847 (1994).
8. Herman, J.G. et al., Silencing of the VHL tumor-suppressor gene by DNA inethylation in renal carcinoma. Proc. natn. Acad. Sci. U.S.A. 91, 9700-9704 (1994).
9. Lathe, R. Synthetic oligonucleotide probes deduced from amino acid sequence data, theoretical and practical considerations. J. molec. Biol. 183, 1-12 (1985).
10. Kuzmin, I. et al., Identification of the promoter of the human von HippelLindau disease tumor suppressor gene. Oncogene (in the press).
11. Kozak, M. At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J. molec. Biol. 196, 947-950 (1987).
12. Kozak, M. The scanning model for translation: An update. J. Cell Biol. 108, 229-241 (1989).
13. Shimizu, M. et al., Introduction of normal chromosome 3p modulates the tumori- genicity of a human renal cell carcinoma cell line YCR. Oncogene 5, 185-194 (1990).
14. Yoshida, M.A. et al., in vivo growth suppression and morphological change in a human renal cell carcinoma cell line by the introduction of normal chromosome 3 via microcell fusion. Molec. Carcinog. 9, 114-121 (1994).
15. Golde, D.W. & Hocking, W.G. Polycythemia: Mechanisms and management. Ann. intern. Med. 95, 71-87 (1981).
16. Linehan, W.M., Lerman, M.I. & Zbar, B. Identification of the von HippelLindau (VHL) gene. JAMA 273, 564-70 (1995).
17. Graham, F.L., Smiley, J., Russell, W.C. & Nairn, R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59-72 (1977).
18. Graham, F.L. & van der Eb, A. A new technique for the assay of infectivity of human adenovirus 5 DNA. J. Virol. 52, 456-467 (1973).
19. Kaelin, W.G., Ewen, M.E. & Livingston, D.M., Definition of the minimal simian virus 40 large T antigen- and adenovirus ElA-binding domain in the retinoblastoma gene product. Molec. cell. Bioh 10, 3761-3769 (1990).
20. DeCaprio, J.A. et al., SV40 large T antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 54, 275-283 (1988).
21. Kaelin, W.G. et al., Expression cloning of a cDNA encoding a retinoblastomabinding protein with E2F-like properties. Cell 70, 351-364 (1992).
22. Krek, W., Livingston, D.M. & Shirodkar, S. Binding to DNA and retinoblastoma gene product promoted by complex formation of different E2F family members. Science 262, 1557-1560 (1993).
23. Smith, D.B. & Johnson, K.S. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene 67, 31-40 (1988).
24. Qin, X.-Q., Livingston, D.M., Kaelin, W.G. & Adams, P. Deregulated E2F1 expression leads to S-phase entry and p53-mediated apoptosis. Proc. natn. Acad. Sci. U.S.A. 91, 10918-10922 (1994).
25. Qin, X.-Q. etah The transcription factor E2F1 is a downstream target of RB action. Molec. cell. Bioh 15, 742-755 (1995).
26. Harlow, E. & Lane, D. Antibodies — A laboratory manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1988).
27. Lee, W.-H. et al., The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity. Nature 329, 642-645 (1987).
28. Radke, K.V. et al., Membrane association of a 36, 000-Dalton substrate for tyrosine phosphorylation in chicken embryo fibroblasts transformed by avian sarcoma viruses. J. cell Bioh 97, 1601-1611 (1983).
29. Qin, X.-Q., Chittenden, T., Livingston, D.M. & Kaelin, W.G. Identification of a growth suppression domain within the retinoblastoma gene product. Genes Dev. 6, 953-964 (1992).
30. Chomczynski, P. & Sacchi, N. Single step method of RNA isolation by acid guadinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162, 156-159 (1987).